Savient Pharmaceuticals, Inc. (SVNT) Cash Flow Statement

Click line-items for a historical chart and %

Net loss	-70.31M
Depreciation and amortization	344K
Accretion of discount on convertible notes	12.82M
Change in valuation of warrant liability
Warrant liability transferred to APIC upon exercise of warrant
Amortization of deferred compensation related to restricted stock (including restricted stock awards that contain performance conditions)
Amortization of deferred financing costs	651K
Unrecognized tax benefit liability
Deferred income taxes
Stock compensation expense	3.26M
Accounts receivable, net	-2.48M
Inventories, net	3.06M
Recoverable income taxes
Prepaid expenses and other current assets	-261K
Accounts payable	-1.82M
Accrued interest on convertible notes
Other current liabilities	-200K
Deferred revenues	193K
Net cash used in operating activities	-61.96M
Purchases of held-to-maturity securities (investments-short-term)	-520K
Capital expenditures
Changes in other long-term assets
Net cash used in investing activities	40.54M
Proceeds from issuance of common stock	139K
Proceeds from issuance of convertible notes, net of expenses
Changes in other long-term liabilities
Net cash provided by financing activities	139K
Net increase (decrease) in cash and cash equivalents	-21.89M
Cash and cash equivalents at beginning of period	50.33M
Cash and cash equivalents at end of period	28.44M
Income tax paid	0
Interest paid	8.38M

Entities mentioned with SVNT

View All Entities